UBS AM
ANAB icon

UBS AM’s AnaptysBio ANAB Stock Holding History

UBS AM’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57M Sell
23,310
-7,417
-24% -$450K ﹤0.01% 2165
2026
Q1 		$1.7M Buy
30,727
+219
+0.7% +$11.8K ﹤0.01% 2116
2025
Q4 		$1.48M Sell
30,508
-2,763
-8% -$108K ﹤0.01% 1996
2025
Q3 		$1.02M Sell
33,271
-16,534
-33% -$379K ﹤0.01% 2004
2025
Q2 		$1.11M Buy
49,805
+14,892
+43% +$312K ﹤0.01% 2366
2025
Q1 		$649K Buy
34,913
+5,434
+18% +$90.7K ﹤0.01% 2441
2024
Q4 		$390K Sell
29,479
-3,405
-10% -$82.5K ﹤0.01% 2587
2024
Q3 		$1.1M Buy
32,884
+3,223
+11% +$110K ﹤0.01% 2355
2024
Q2 		$743K Buy
29,661
+12,740
+75% +$297K ﹤0.01% 2506
2024
Q1 		$381K Hold
16,921
– – ﹤0.01% 2351
2023
Q4 		$362K Hold
16,921
– – ﹤0.01% 2388
2023
Q3 		$304K Hold
16,921
– – ﹤0.01% 2433
2023
Q2 		$368K Hold
16,921
– – ﹤0.01% 2413
2023
Q1 		$368K Buy
+16,921
New +$411K ﹤0.01% 2413
2022
Q4 		– Sell
-23,007
Closed -$587K – 2560
2022
Q3 		$587K Buy
23,007
+8,361
+57% +$196K ﹤0.01% 2274
2022
Q2 		$297K Sell
14,646
-8,361
-36% -$185K ﹤0.01% 2482
2022
Q1 		$569K Hold
23,007
– – ﹤0.01% 2421
2021
Q4 		$799K Sell
23,007
-1,307
-5% -$41.4K ﹤0.01% 2328
2021
Q3 		$659K Hold
24,314
– – ﹤0.01% 2369
2021
Q2 		$630K Buy
24,314
+9,668
+66% +$232K ﹤0.01% 2443
2021
Q1 		$316K Sell
14,646
-2,227
-13% -$56.2K ﹤0.01% 2479
2020
Q4 		$363K Hold
16,873
– – ﹤0.01% 2382
2020
Q3 		$249K Hold
16,873
– – ﹤0.01% 2347
2020
Q2 		$377K Buy
16,873
+2,524
+18% +$46.1K ﹤0.01% 2223
2020
Q1 		$203K Buy
+14,349
New +$218K ﹤0.01% 2275
2019
Q4 		– Sell
-99,518
Closed -$3.48M – 2542
2019
Q3 		$3.48M Sell
99,518
-2,516
-2% -$120K ﹤0.01% 1355
2019
Q2 		$5.76M Buy
102,034
+4,164
+4% +$300K ﹤0.01% 1154
2019
Q1 		$7.15M Buy
97,870
+3,935
+4% +$272K 0.01% 1031
2018
Q4 		$5.99M Sell
93,935
-9,813
-9% -$730K 0.01% 1022
2018
Q3 		$10.4M Buy
103,748
+10,098
+11% +$838K 0.01% 928
2018
Q2 		$6.65M Buy
93,650
+22,193
+31% +$1.86M 0.01% 1057
2018
Q1 		$7.44M Buy
71,457
+83
+0.1% +$9.35K 0.01% 1009
2017
Q4 		$7.19M Buy
+71,374
New +$5.25M 0.01% 996

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

UBS AM's ANAB Position: Q2 2026 in Review

UBS AM reduced its AnaptysBio (ANAB) stake by 24% in Q2 2026, selling an estimated $450K and leaving 23,310 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2165.

UBS AM first reported a position in ANAB in Q4 2017 and has held it in 33 quarters since. The position peaked at $10.4M in Q3 2018. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • UBS AM held 23,310 shares of AnaptysBio worth $1.57M as of Q2 2026.
  • UBS AM sold 7,417 AnaptysBio shares in Q2 2026, an estimated $450K.
  • AnaptysBio made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2165 holding.
  • UBS AM first reported a position in AnaptysBio in Q4 2017 and has held it in 33 quarters since.
  • UBS AM's AnaptysBio position peaked at $10.4M in Q3 2018.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.